The New England journal of medicine, 2020-04, Vol.382 (14), p.1331-1342
- Wang, Michael
- Munoz, Javier
- Goy, Andre
- Locke, Frederick L
- Jacobson, Caron A
- Hill, Brian T
- Timmerman, John M
- Holmes, Houston
- Jaglowski, Samantha
- Flinn, Ian W
- McSweeney, Peter A
- Miklos, David B
- Pagel, John M
- Kersten, Marie-Jose
- Milpied, Noel
- Fung, Henry
- Topp, Max S
- Houot, Roch
- Beitinjaneh, Amer
- Peng, Weimin
- Zheng, Lianqing
- Rossi, John M
- Jain, Rajul K
- Rao, Arati V
- Reagan, Patrick M
2020
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Wang, Michael
- Munoz, Javier
- Goy, Andre
- Locke, Frederick L
- Jacobson, Caron A
- Hill, Brian T
- Timmerman, John M
- Holmes, Houston
- Jaglowski, Samantha
- Flinn, Ian W
- McSweeney, Peter A
- Miklos, David B
- Pagel, John M
- Kersten, Marie-Jose
- Milpied, Noel
- Fung, Henry
- Topp, Max S
- Houot, Roch
- Beitinjaneh, Amer
- Peng, Weimin
- Zheng, Lianqing
- Rossi, John M
- Jain, Rajul K
- Rao, Arati V
- Reagan, Patrick M
- Titel
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- Ist Teil von
- The New England journal of medicine, 2020-04, Vol.382 (14), p.1331-1342
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2020
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Patients with mantle-cell lymphoma who have a relapse after chemotherapy and anti-CD20 and BTK inhibitor therapy have a poor prognosis. An injection of CD19-directed CAR T cells induced a complete response in 59% of patients; 78% with a complete response were in remission at 1 year. About two thirds of patients had serious adverse events, a finding consistent with previous data.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa1914347Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7731441
- Format
- –
- Schlagworte
- Adult, Aged, Antigens, CD19 - therapeutic use, Antineoplastic Agents - therapeutic use, Body weight, Bruton's tyrosine kinase, CD19 antigen, Cell therapy, Chemotherapy, Chimeric antigen receptors, Combined Modality Therapy, Enzyme inhibitors, Humans, Immunotherapy, Adoptive - adverse effects, Independent sample, Infusions, Intravenous, Leukapheresis, Leukemia, Lymphocytes, Lymphocytes T, Lymphoma, Lymphoma, Mantle-Cell - drug therapy, Lymphoma, Mantle-Cell - mortality, Lymphoma, Mantle-Cell - therapy, Manufacturing, Medical prognosis, Middle Aged, Patients, Protein-tyrosine kinase, Receptors, Chimeric Antigen - antagonists & inhibitors, Recurrence, Remission, Statistical analysis, Survival Analysis, T-Lymphocytes - transplantation, Vidarabine - analogs & derivatives, Vidarabine - therapeutic use